



USA

CAN ELIMINATE HEPATITIS

NATIONAL HEPATITIS ELIMINATION PROFILE

UPDATED JULY 27 2021



Hepatitis B virus (HBV)

Hepatitis C virus (HCV)

2030

HBV elimination goal

2030

Elimination of HBV mother to child transmission ¹

2030

HCV elimination goal



IN 2021, THE US GOVERNMENT COMMITTED TO REACHING GOALS FOR HEPATITIS ELIMINATION

THE HEALTH BURDEN OF VIRAL HEPATITIS

862,000–2.4M

Number of persons living with HBV infection, 2016

Based on national survey

Asian Americans, Pacific Islanders, and African-Born persons account for 50-80% of infections ^{4,7}



Prevalence

REGIONAL AVERAGE IN THE AMERICAS:
HBV: 0.3%
HCV: 0.7%

2.4 M (2.0-2.8 M)

Number of persons living with HCV infection, 2015

Based on national survey

75% of persons with chronic HCV were born from 1945 through 1965 ⁵

20,700

New HBV cases, 2019 ³²

Incidence highest among persons aged 30-49 years, those most affected by the opioid epidemic ³²



Incidence

57,500

New HCV cases, 2019 ³³

Incidence highest among those aged 20-39 years and American Indians and Alaska Natives, those most affected by the opioid epidemic ³³

1,662

HBV deaths, 2019 ³²

.42 Deaths per 100,000

Death rate among Asian and Pacific Islanders is 5 times the rate among White Americans ³²



Mortality

14,242

HCV deaths, 2019 ³³


3.33 Deaths per 100,000

Death rate among Black Americans is almost 2 times the rate among White Americans ³³

PROGRESS TOWARDS 2020 WHO ELIMINATION GOALS

PREVENTION OF NEW INFECTIONS AND MORTALITY

HBV Percentage change in new infections 2015-2019




-5%



WHO 2020 Target -30% (US 2025 Target <18,000 cases) ³²

HBV Percentage change in deaths 2015-2019



-3%



WHO 2020 Target -10% (US 2025 Target Rate 0.37/100,000) ³²

HCV Percentage change in new infections 2015-2019



+70%



WHO 2020 Target -30% (US 2025 Target <25,000 cases) ³³

HCV Percentage change in deaths 2015-2019



-27%



WHO 2020 Target -10% (US 2025 Target Rate 3.00/100,000) ³³

Prevalence of HBsAg in children < 5 years (%) 2019

0.03 (0.02-0.04)%

SDG 2020 Target 1% ²



ACCESS TO RECOMMENDED VACCINATION, TESTING AND TREATMENT



76% Hepatitis B vaccination coverage for newborns, 2017 ¹⁰

WHO 2020 Target 50% (US 2025 Target 75%) ¹⁰




91% HepB 3 dose vaccine coverage for infants, 2017 ¹⁰

WHO 2020 Target 90%



32% Proportion of persons living with **HBV** diagnosed, 2016

WHO 2020 Target 30% (US 2025 Target 50%)



18%

HBV

Proportion of diagnosed HBV persons receiving appropriate treatment ¹²

30


For persons who inject drugs (PWID), number of sterile needles per year ¹¹


WHO 2020 Target 200



60% Proportion of persons living with **HCV** diagnosed, 2016 ¹

WHO 2020 Target 30%





POLICY ENVIRONMENT FOR THE ELIMINATION OF HEPATITIS

ACHIEVEMENT

INNOVATIONS

ROADBLOCKS

STRATEGIC INFORMATION

Routine official reports to monitor HBV and HCV ^{2,3}



Estimates of HBV and/or HCV economic burden ^{13,14}

Adopted

Monitoring of HBV and HCV diagnosis and treatment ^{15,16}

Partially Adopted

ROADBLOCKS
Inadequate surveillance data to guide service delivery for at-risk populations



PREVENTION OF MOTHER TO CHILDREN TRANSMISSION

Policy for hepatitis B vaccination of newborns ¹

Adopted

Recommendations for:

HBV testing of pregnant women ¹

Adopted

HCV testing of pregnant women ¹⁷

Adopted

Program for triple elimination of HIV, hepatitis B, and syphilis

Adopted



ACHIEVEMENTS

Hep B Moms initiative to educate pregnant women at risk of, or infected with hepatitis B

ACCESS AND REGISTRATION OF MEDICINES AND TESTS

HCV: Registration of originator medicines ³¹

Adopted

HCV: Eligible for generic medicines

Not Eligible

HCV: Registration of generic medicines

Not Applicable

Licensed point-of-care PCR testing to detect HBV and HCV

Not Adopted

TESTING TO DIAGNOSE HBV AND HCV INFECTION

Testing recommendations for:

HBV: Risk-based ²⁰

Adopted

HBV: Persons born in regions with prevalence >2% ²⁰

Adopted



HCV: Risk-based ¹⁷

Adopted

HCV: Universal One-Time ¹⁷

Adopted

No patient co-pays for HBsAg and anti-HCV testing ²¹

Adopted



ROADBLOCKS

Limited access to HCV testing in emergency departments



ACHIEVEMENTS

All-adult HCV testing recommendations (2020)

ACCESS TO HBV AND HCV TREATMENT

HBV: National treatment guidelines ³⁰

Develop[ed]

Simplified care: No patient treatment co-pays

Partially Adopted

HCV: National treatment guidelines ²²

Available

Simplified care algorithm: Less than 2 clinic visits during treatment ²²

Adopted

Simplified care algorithm: Non-specialists can prescribe treatment ²³

Partially Adopted

34 of 52 states/territories have removed prescribing restriction

Simplified care algorithm: No patient treatment co-pays

Partially Adopted

Varies by payer

No fibrosis restrictions ²³

Partially Adopted

48 of 52 states/territories

No sobriety restrictions ²³

Partially Adopted

24 of 52 states/territories

No genotyping ²²

Adopted





ACHIEVEMENTS

Simplified hepatitis B treatment and monitoring algorithm for primary care providers developed

Increasing number of states removing fibrosis, sobriety, and prescribing restrictions



INNOVATIONS

Project ECHO tele-mentoring to expand access to HBV and HCV treatment in under-served areas

Sub-national HCV elimination programs, including Cherokee Nation, San Francisco, and Louisiana



ROADBLOCKS

Cost of HCV testing in emergency departments and other priority settings beyond primary care

Hepatitis B treatment remains unaffordable or out of reach to many patients due to discriminatory practices by insurance companies

Inequities in access and affordability of HBV and HCV testing, care, and treatment

Unnecessary complexity of HCV care and treatment

HEALTH EQUITY AND ADDRESSING DISPARITIES

National strategy addresses populations most affected ¹

Adopted

National anti-discrimination laws against persons living with hepatitis B and/or C ²⁵

Partially Adopted

National policy for adult hepatitis B vaccination ²⁸

Adopted

National policy for:

Harm reduction for persons who inject drugs (PWID) ¹⁸

Developed

Syringe exchange in federal prisons ¹⁸

Not Adopted

Number of needles/syringes per PWID per year ¹¹

30

WHO 2020 Target 200

Number of opioid substitution therapy recipients per 100 PWID ¹⁸

Not Adopted



Decriminalization of possession of syringes & paraphernalia

Partially Adopted

3 of 51 states/territories (inc. DC)

Decriminalization of drug use ¹⁸

Not Adopted

Decriminalization of hepatitis infection ²⁹

Partially Adopted

12 of 50 states have laws that criminalize hepatitis



INNOVATIONS

The HIT-B program was a program at a community health clinic primarily serving medically underserved Asian American patient mined electronic health record (EHR) data on HBV screening and vaccination history to provide point-of-care recommendations that resulted in improvement in HBV screening and vaccination rates.

Community-based HCV testing and referral to care for homeless persons (e.g. Los Angeles)

New York State's Drug User Health hubs, which co-locate HCV treatment at syringe exchange programs

Increased US CDC support for hepatitis prevention, diagnosis, and treatment for PWID



ACHIEVEMENTS

Federal support for harm reduction awarded in the American Rescue Plan (2021)



ROADBLOCKS

Substantial racial/ethnic disparities in HBV and HCV incidence and mortality

Limited access to harm reduction, safe injection equipment, and opioid substitution therapy for PWID

FINANCING

Public budget line for HBV and HCV testing and treatment ²⁴

Adopted



INNOVATIONS

Innovative Medicaid financing programs, i.e. subscription models in Louisiana and Washington state



NEXT STEPS TOWARD ELIMINATION



Increase support for hepatitis surveillance linked to program planning and targeting service delivery



Guided by strategic information, expand access to harm reduction, including in correctional settings



Prioritize programs and partnerships to address hepatitis-related health disparities



Pursue policies to expand access to HepB vaccination, care and treatment



Scale-up HCV testing for all-adults, including for pregnant women



Expedite FDA licensure of point-of-care HBV and HCV diagnostic tests



Remove restrictions to HCV treatment (e.g. sobriety restrictions)



Leverage innovations from COVID-19 response (e.g. home-based testing)

SOURCES

1. U.S. Department of Health and Human Services. 2020. Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021–2025). Washington, DC. <https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf>
2. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance Report 2018— Hepatitis B. <https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepB.htm>
3. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance Report 2018 —Hepatitis C. <https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepC.htm>
4. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011–2016. *Clin Infect Dis*. 2019 Aug 1;69(4):709–712. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669285/>
5. Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, Mermin J, Ward JW, Ryerson AB. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013–2016. *Hepatology*. 2019 Mar;69(3):1020–1031. doi: 10.1002/hep.30297. Epub 2018 Nov 6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719781/>
6. U.S. Department of Health and Human Services. 2014. 2014–2016 Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis. Washington, DC. <https://www.hhs.gov/sites/default/files/viral-hepatitis-action-plan.pdf>
7. Wong, R.J., Brosgart, C.L., Welch, S., Block, T., Chen, M., Cohen, C., Kim, W.R., Kowdley, K.V., Lok, A.S., Tsai, N., Ward, J., Wong, S.S., Gish, R.G., 2021. An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. *Hepatology*. doi:10.1002/hep.31782 <https://pubmed.ncbi.nlm.nih.gov/33655536/>
8. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance Report 2019. <https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm>
9. IHME. Global Burden of Disease Study. 2019 <https://www.globalhep.org/country-progress/united-states-america>
10. Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Pingali SC, Santibanez TA. Vaccination Coverage by Age 24 Months Among Children Born in 2016 and 2017 — National Immunization Survey-Child, United States, 2017–2019. *MMWR Morb Mortal Wkly Rep* 2020;69:1505–1511.
11. Larney S et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among persons who inject drugs: a systematic review. *Lancet Glob Health*. 2017 Dec;5(12):e1208–e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(17\)30373-X/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30373-X/fulltext)
12. Harris AM, Osinubi A, Nelson NP, Thompson WW. The hepatitis B care cascade using administrative claims data, 2016. *Am J Manag Care*. 2020 Aug;26(8):331–338. doi: 10.37765/ajmc.2020.44069. PMID: 32835460. <https://www.ajmc.com/view/the-hepatitis-b-care-cascade-using-administrative-claims-data-2016>



13. Toy M, Hutton DW, So S. Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. *Health Aff (Millwood)*. 2018 Jul;37(7):1033-1040. <https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2018.0035>
14. Roebuck MC, Liberman JN. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid. *Am J Manag Care*. 2019 Jun;25(8 Suppl):S131-S139. PMID: 31211526 <https://www.ajmc.com/view/assessing-burden-illness-chronic-hepatitis-impact-antiviral-healthcare-costs-medicaid>
15. Isenhour C, Hariri S, Vellozzi C. Monitoring the hepatitis C care cascade using administrative claims data. *Am J Manag Care*. 2018; May;24(5):232-238. PMID: 29851440; PMCID: PMC6371394. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371394/>
16. Harris, A. M., Osinubi, A., Nelson, N. P., & Thompson, W. W. (2020). The hepatitis B care cascade using administrative claims data, 2016. *The American journal of managed care*, 26(8), 331-338. <https://doi.org/10.37765/ajmc.2020.44069> <https://pubmed.ncbi.nlm.nih.gov/32835460/>
17. CDC Recommendations for Hepatitis C Screening Among Adults – United States, 2020. *MMWR* 2020 (RR 69) <https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm>
18. Georgetown HIV Policy Lab. <https://www.hivpolicylab.org/us> <https://www.hivpolicylab.org/us>
19. Fernández-Viña MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State Laws Governing Syringe Services Programs and Participant Syringe Possession, 2014-2019. *Public Health Rep*. 2020 Jul/Aug;135(1_suppl):128S-137S. <https://journals.sagepub.com/doi/full/10.1177/0033354920921817>
20. Centers for Disease Control and Prevention. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. *MMWR* 2008; 57 (No. RR-8). <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm>
21. U.S Department of Health and Human Service. Viral Hepatitis and the Affordable Care Act. Accessed 27 April 2021. <https://www.hhs.gov/hepatitis/policies-and-guidelines/affordable-care-act/index.html>
22. AASLD-IDSAs. Recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org/>
23. Center for Health Law and Policy Innovation, Harvard Law School. Hepatitis C: The State of Medicaid Access: 4/1/2021 update. <https://perma.cc/UY2C-DQZG>. Accessed April 23, 2021. https://www.chlpi.org/wp-content/uploads/2013/12/HCV_State-of-Medicaid-Access_August-2020-update-v2.pdf
24. US CDC. CDC's Viral Hepatitis Work Saves Lives and Money. Accessed 27 April 2021. <https://www.cdc.gov/nchhstp/budget/infographics/viral-hepatitis.html>
25. Hepatitis B Foundation. Know Your Rights: Legal Protections for Those Living With Hepatitis B. Accessed 27 April 2021. <https://www.hepb.org/blog/know-rights-legal-protections-living-hepatitis-b/>
26. Fuster D, Gelberg L. Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. *J Community Health*. 2019 Dec;44(6):1044-1054. <https://pubmed.ncbi.nlm.nih.gov/31127412/>
27. HBV Primary Care Work Group (2021). HBV Management: Guidance for the Primary Care Provider. <https://www.hepatitisb.uw.edu/page/primary-care-workgroup/guidance>
28. Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018). Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports*, 67(1), 1-31. <https://doi.org/10.15585/mmwr.rr6701a1> <https://pubmed.ncbi.nlm.nih.gov/29939980/>
29. The Center for HIV Law and Policy (2020). <https://www.hivlawandpolicy.org/sites/default/files/An%20Overview%20of%20States%20Criminalizing%20Viral%20Hepatitis%20Map%20%282020%29.pdf>
30. Terrault, N. A., Lok, A., McMahon, B. J., Chang, K. M., Hwang, J. P., Jonas, M. M., Brown, R. S., Jr, Bzowej, N. H., & Wong, J. B. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology (Baltimore, Md.)*, 67(4), 1560-1599. <https://doi.org/10.1002/hep.29800> <https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800>
31. US Food and Drug Administration. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process>
32. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance Report 2019—Hepatitis B. <https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepB.htm>
33. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance Report 2019—Hepatitis C. <https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepC.htm>

WORKING TOGETHER, WE WILL ACHIEVE ELIMINATION.



COALITION
FOR GLOBAL
HEPATITIS
ELIMINATION

This National Hepatitis Elimination Profile (N-HEP) was developed by the Coalition for Global Hepatitis Elimination. Funding for this N-HEP was provided by Gilead Sciences. The Coalition for Global Hepatitis Elimination retained final control over the content.

FOR MORE INFORMATION:
GLOBALHEP.ORG
GLOBALHEP@TASKFORCE.ORG

The Coalition thanks AASLD, Hepatitis B Foundation, NASTAD, National Viral Hepatitis Roundtable (NVHR), US CDC, and Norah Terrault for their review and feedback. The Coalition also is grateful to the Pan-American Health Organization for their strategic guidance and input on the design of the profile.

TASKFORCE.ORG
330 W. PONCE DE LEON AVENUE
DECATUR GA 30030

